BE2016C069I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C069I2
BE2016C069I2 BE2016C069C BE2016C069C BE2016C069I2 BE 2016C069 I2 BE2016C069 I2 BE 2016C069I2 BE 2016C069 C BE2016C069 C BE 2016C069C BE 2016C069 C BE2016C069 C BE 2016C069C BE 2016C069 I2 BE2016C069 I2 BE 2016C069I2
Authority
BE
Belgium
Application number
BE2016C069C
Other languages
French (fr)
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of BE2016C069I2 publication Critical patent/BE2016C069I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2016C069C 2002-01-28 2016-12-12 BE2016C069I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (en) 2002-01-28 2002-01-28 NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
PCT/FR2003/000243 WO2003063864A2 (en) 2002-01-28 2003-01-27 Heterocyclic compounds which are active as inhibitors of beta lactamases

Publications (1)

Publication Number Publication Date
BE2016C069I2 true BE2016C069I2 (en) 2022-05-17

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C069C BE2016C069I2 (en) 2002-01-28 2016-12-12

Country Status (44)

Country Link
US (4) US7612087B2 (en)
EP (2) EP2279737B1 (en)
JP (1) JP4472346B2 (en)
KR (1) KR100979079B1 (en)
CN (3) CN101406471A (en)
AR (2) AR038234A1 (en)
AT (1) ATE484281T1 (en)
AU (1) AU2003214335B2 (en)
BE (1) BE2016C069I2 (en)
BR (1) BRPI0307267B8 (en)
CA (1) CA2474043C (en)
CL (1) CL2011000009A1 (en)
CO (1) CO5601014A2 (en)
CR (2) CR7387A (en)
CY (3) CY1111061T1 (en)
DE (1) DE60334527D1 (en)
DK (2) DK2279737T3 (en)
EA (1) EA007220B1 (en)
EC (1) ECSP045193A (en)
ES (2) ES2356813T3 (en)
FR (2) FR2835186B1 (en)
HR (1) HRP20040686B1 (en)
HU (1) HUS1600055I1 (en)
IL (1) IL163167A (en)
JO (1) JO2646B1 (en)
LT (1) LTC1480644I2 (en)
MA (1) MA26351A1 (en)
MX (1) MXPA04006621A (en)
MY (1) MY140638A (en)
NL (1) NL300847I2 (en)
NO (3) NO335195B1 (en)
NZ (1) NZ533936A (en)
OA (1) OA12761A (en)
PE (1) PE20030969A1 (en)
PL (1) PL220725B1 (en)
PT (2) PT1480644E (en)
RS (1) RS52137B (en)
SI (2) SI2279737T1 (en)
TN (1) TNSN04137A1 (en)
TW (1) TWI293071B (en)
UA (1) UA80271C2 (en)
UY (1) UY27626A1 (en)
WO (1) WO2003063864A2 (en)
ZA (1) ZA200405607B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
FR2844273B1 (en) 2002-09-05 2008-04-04 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (en) * 2002-12-06 2007-10-19 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIALS AND INHIBITORS OF BETA-LACTAMASES
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
CA2629570C (en) * 2005-12-07 2012-11-27 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
WO2008051763A1 (en) * 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (en) * 2007-09-14 2012-06-15 Novexel NOVEL PROCESS FOR PREPARING DISUBSIDED PIPERIDINE AND NOVEL INTERMEDIATES
PT2231667E (en) * 2008-01-18 2013-12-13 Merck Sharp & Dohme Beta-lactamase inhibitors
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (en) * 2008-04-29 2010-05-21 Novexel AZABICYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR BETA-LACTAMASES INHIBITORS
US8518934B2 (en) * 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (en) * 2008-10-03 2012-09-28 Novexel NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES.
FR2936951B1 (en) * 2008-10-10 2010-12-03 Novexel NOVEL COMBINATIONS OF ANTIBACTERIAL NITROGENIC HETEROCYCLIC COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THEIR USE AS MEDICAMENTS
FR2937034B1 (en) * 2008-10-10 2012-11-23 Novexel NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES
FR2951171A1 (en) * 2009-10-09 2011-04-15 Novexel NOVEL SODIUM SALT OF A CRYSTALLIZED ENANTIOMER AZABICYCLIC COMPOUND AND NOVEL POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS AND THEIR PREPARATION
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
SG187757A1 (en) 2010-08-10 2013-03-28 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2011346224B2 (en) * 2010-12-22 2017-04-06 Meiji Seika Pharma Co., Ltd. Optically-active diazabicyclooctane derivative and method for manufacturing same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
EP2721005B1 (en) 2011-06-17 2015-11-25 AstraZeneca AB Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
PL2748165T3 (en) * 2011-08-27 2017-05-31 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8754102B2 (en) * 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
JP2015514095A (en) 2012-03-30 2015-05-18 キュービスト ファーマシューティカルズ, インコーポレイテッド 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (en) * 2012-04-02 2014-11-19 Astrazeneca Ab INHIBITING COMPOUNDS OF B LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2013180197A1 (en) * 2012-05-30 2013-12-05 Meiji Seikaファルマ株式会社 NOVEL β-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
NZ626314A (en) * 2012-08-25 2017-02-24 Wockhardt Ltd 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
UA111925C2 (en) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112015016002A2 (en) 2013-01-04 2017-07-11 Rempex Pharmaceuticals Inc compounds, pharmaceutical compositions, chemical complexes and their uses and method for treating or preventing bacterial infection
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
MX372585B (en) 2013-09-24 2020-04-17 Meiji Seika Pharma Co Ltd PROCESS FOR PRODUCING DIAZABICICLOOCTONE DERIVATIVE AND ITS INTERMEDIATE
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CA2926071C (en) 2013-10-08 2021-11-09 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
EP3107539A1 (en) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (en) * 2014-03-20 2014-07-02 西安交通大学 (5S, 6R) cloxacillin penicilloate as well as preparation method and application thereof
ES2972939T3 (en) 2014-05-05 2024-06-17 Melinta Therapeutics Inc Synthesis of boronate salts
ES2985626T3 (en) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201691988A1 (en) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
CN104059083B (en) * 2014-05-27 2017-01-04 浙江工业大学 asymmetric synthesis method of chiral dicyclo caprolactam compound
KR20170024087A (en) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 Boronic acid derivatives and therapeutic uses thereof
ME03357B (en) 2014-11-17 2019-10-20 Entasis Therapeutics Ltd Combination therapy for treatment of resistant bacterial infections
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
SG11201704576SA (en) 2014-12-05 2017-07-28 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2017014080A (en) * 2015-05-07 2018-07-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections.
CA2984024A1 (en) * 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
EA201890847A1 (en) 2015-10-02 2018-08-31 Легокем Байосайенсез, Инк. COMPOSITIONS AND METHODS FOR INHIBITING BETA LACTAMASE
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (en) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Dihydrooxadiazine compounds to treat infections and cancer
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (en) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 A kind of method synthesizing A Wei Batan and intermediate optical isomer thereof
CN107789355B (en) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 Compound pharmaceutical composition containing piperacillin and application thereof
MX385507B (en) 2016-09-16 2025-03-18 Entasis Therapeutics Ltd BETA-LACTAMASE INHIBITING COMPOUNDS
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
CN106699756B (en) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 The synthetic method of beta lactamase restrainer AVM hereinafter Batan
US20200017496A1 (en) 2017-02-06 2020-01-16 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
SI3630111T1 (en) 2017-05-08 2022-05-31 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
JP7377545B2 (en) 2017-10-11 2023-11-10 キューペックス バイオファーマ, インコーポレイテッド Boronic acid derivatives and their synthesis
CN109678856B (en) * 2017-10-18 2020-09-25 新发药业有限公司 Preparation method of avibactam intermediate
WO2019093450A1 (en) * 2017-11-10 2019-05-16 塩野義製薬株式会社 Diazabicyclooctane derivative
JP7329260B2 (en) 2018-04-20 2023-08-18 キューペックス バイオファーマ, インコーポレイテッド Boronic acid derivatives and their therapeutic use
HRP20231228T1 (en) 2018-08-09 2024-01-19 Antabio Sas DIAZABICYCLOOKTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (en) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 Beta-lactamase inhibitor urea-containing bicyclic compound and preparation method and application thereof
EP4146650A4 (en) * 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
CN115605480B (en) 2021-05-07 2024-04-05 宁夏农林科学院 Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (en) 2022-09-23 2024-04-01 주식회사 경보제약 Stable monohydrate form of avibactam sodium and manufacturaing method thereof
CN116375706B (en) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 Key intermediate of avibactam sodium and preparation method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
CA2051697C (en) 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
FR2676230B1 (en) 1991-05-07 1993-08-27 Centre Nat Rech Scient NOVEL PYRROLO [1,4] -BENZODIAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM.
JPH05339263A (en) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd Dihydropyridine derivative
ES2182847T3 (en) 1993-09-29 2003-03-16 Nabi NUCLEOSIDS AND NUCLEOTIDES OF EXPANDED RING.
KR100197454B1 (en) * 1993-12-29 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 Diazabicyclic neurokinin antagonists
EP0702004A2 (en) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (en) 1995-12-22 1995-12-22 Astra Ab New Compounds
AP9801283A0 (en) * 1996-01-03 1998-09-30 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials.
DE19627431A1 (en) 1996-07-08 1998-01-15 Bayer Ag Heterocyclically fused pyridines
UA51716C2 (en) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. combinations possessing hypotensive, cardioprotective, anti-ishemic, and antilipolytic agents, a pharmaceutical composition and METHOD OF TREATMENT
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (en) * 1997-10-29 2000-12-29 Smithkline Beecham Plc PLEUROMUTILINE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS
CA2327695A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
WO2000037458A1 (en) 1998-12-18 2000-06-29 Schering Corporation Farnesyl protein transferase inhibitors
CO5180550A1 (en) 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
US7179921B2 (en) 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (en) 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
PL371601A1 (en) 2005-06-27
ZA200405607B (en) 2005-09-28
JP2005523897A (en) 2005-08-11
AU2003214335B2 (en) 2007-04-05
EA007220B1 (en) 2006-08-25
WO2003063864A2 (en) 2003-08-07
BR0307267A (en) 2004-12-07
NO335195B1 (en) 2014-10-20
CA2474043C (en) 2011-08-02
HRP20040686B1 (en) 2013-02-28
AR038234A1 (en) 2005-01-05
DE60334527D1 (en) 2010-11-25
LTPA2016037I1 (en) 2017-01-10
PL220725B1 (en) 2015-12-31
FR2835186A1 (en) 2003-08-01
US20090215747A1 (en) 2009-08-27
EP2279737A1 (en) 2011-02-02
NO2025027I1 (en) 2025-06-13
NZ533936A (en) 2007-05-31
CN100482225C (en) 2009-04-29
NO2016024I1 (en) 2016-12-15
YU65804A (en) 2006-08-17
CA2474043A1 (en) 2003-08-07
RS52137B (en) 2012-08-31
PE20030969A1 (en) 2003-12-12
TW200303305A (en) 2003-09-01
TWI293071B (en) 2008-02-01
CR7387A (en) 2010-10-25
IL163167A (en) 2010-04-15
EA200400981A1 (en) 2005-02-24
OA12761A (en) 2006-07-04
WO2003063864A3 (en) 2004-03-11
KR100979079B1 (en) 2010-08-31
MY140638A (en) 2010-01-15
SI1480644T1 (en) 2011-03-31
CL2011000009A1 (en) 2011-03-25
ES2356813T3 (en) 2011-04-13
BRPI0307267B8 (en) 2021-05-25
JP4472346B2 (en) 2010-06-02
CY1111061T1 (en) 2015-06-11
US7612087B2 (en) 2009-11-03
PT2279737E (en) 2013-02-01
AR100790A2 (en) 2016-11-02
NL300847I2 (en) 2017-01-03
EP1480644B1 (en) 2010-10-13
CN1655781A (en) 2005-08-17
FR16C1019I2 (en) 2017-12-29
CO5601014A2 (en) 2006-01-31
HK1077205A1 (en) 2006-02-10
NO20043587L (en) 2004-08-27
TNSN04137A1 (en) 2007-03-12
CY2016042I2 (en) 2017-03-15
BRPI0307267B1 (en) 2016-02-10
CN1994301A (en) 2007-07-11
US20100048528A1 (en) 2010-02-25
HRP20040686A2 (en) 2004-12-31
EP2279737B1 (en) 2012-10-31
DK2279737T3 (en) 2013-02-11
CR20120356A (en) 2012-10-05
EP1480644A2 (en) 2004-12-01
KR20040081473A (en) 2004-09-21
LTC1480644I2 (en) 2018-09-10
ECSP045193A (en) 2004-08-27
FR2835186B1 (en) 2006-10-20
HUS1600055I1 (en) 2017-01-30
UY27626A1 (en) 2003-08-29
UA80271C2 (en) 2007-09-10
FR16C1019I1 (en) 2017-02-03
US20050020572A1 (en) 2005-01-27
SI2279737T1 (en) 2013-07-31
CY1114417T1 (en) 2016-08-31
PT1480644E (en) 2011-01-17
HK1105864A1 (en) 2008-02-29
CN100563653C (en) 2009-12-02
CN101406471A (en) 2009-04-15
CY2016042I1 (en) 2017-03-15
ES2401855T3 (en) 2013-04-25
MXPA04006621A (en) 2004-10-04
NO2016024I2 (en) 2016-12-15
JO2646B1 (en) 2012-06-17
MA26351A1 (en) 2004-10-01
DK1480644T3 (en) 2011-01-24
ATE484281T1 (en) 2010-10-15
US20110245254A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
BE2019C547I2 (en)
BE2019C510I2 (en)
BE2018C021I2 (en)
BE2017C049I2 (en)
BE2017C005I2 (en)
BE2016C040I2 (en)
BE2018C018I2 (en)
BE2016C013I2 (en)
BE2015C078I2 (en)
BE2016C002I2 (en)
BE2015C017I2 (en)
BE2014C053I2 (en)
BE2014C041I2 (en)
BE2014C030I2 (en)
BE2014C016I2 (en)
BE2014C015I2 (en)
BE2013C039I2 (en)
BE2011C038I2 (en)
JP2003160408A5 (en)
BE2015C067I2 (en)
JP2003228515A5 (en)
JP2003126679A5 (en)
DE60330807D1 (en)
JP2003216450A5 (en)
HU0202638D0 (en)